Another great Ann... Path to success lined up . Hard to fine any negatives here atm .. The only negative is this SP at this level .... Ahhhhhh
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling